Interventions of Interest
For questions please contact [email protected].
- sibeprenlimab (Voyxact®, Otsuka Holdings Co., Ltd.)
- atacicept (Vera Therapeutics, Inc.)
- delayed-release budesonide (“Nefecon”, Tarpeyo®, Calliditas Therapeutics AB)
IgA Nephropathy
An assessment of sibeprenlimab, budesonide, and atacicept
Public Meeting
February 2026
Assessment Status
Closed
Main Review
February 26, 2026
CTAF Public Meeting
The CTAF’s 2025 public meeting on B-cell-directed therapies
ICER STAKEHOLDER OUTREACH AND PUBLIC COMMENTERS LIST
ICER receives input on its reviews from multiple stakeholders, including patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for stakeholders in any of these categories.
The following is a list of organizations from which ICER has requested input, as well as those that have provided unsolicited public comments during the review. Some organizations on the list may appear only because they were invited to provide input, and it should not be assumed that they have responded to ICER’s outreach or agreed to participate in this review.
- Calliditas Therapeutics AB
- IgA Nephropathy Foundation
- National Kidney Foundation
- NephCure Kidney International
- Otsuka Holdings Co., Ltd.
- Vera Therapeutics, Inc.
To protect patient confidentiality, ICER does not routinely name individual patients or care partners who provided us with input and feedback.
None of these stakeholders are responsible for the final content of ICER’s report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers.
Related Assessments & Policy Papers.
Lupus Nephritis
Mar 2021Anemia in Chronic Kidney Disease
Feb 2021
10/24/2025
Model Analysis Plan
Please find the model analysis plan here: https://osf.io/sk3zn/files/eskdn
12/10/2025
Draft Evidence Report
03/31/2026
Public Comments
Closed